Production (Stage)
Autolus Therapeutics plc
AUTL
$1.54
$0.010.65%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 30,872.41% | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 30,872.41% | -- | |||
| Cost of Revenue | -67.69% | 11,255.01% | |||
| Gross Profit | 74.18% | -11,252.63% | |||
| SG&A Expenses | -30.47% | 55.43% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -2.21% | 12.18% | |||
| Operating Income | 14.01% | -12.14% | |||
| Income Before Tax | -159.85% | 68.15% | |||
| Income Tax Expenses | 52.19% | 6,545.45% | |||
| Earnings from Continuing Operations | -154.15% | 66.37% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -154.15% | 66.37% | |||
| EBIT | 14.01% | -12.14% | |||
| EBITDA | 14.67% | -12.28% | |||
| EPS Basic | -154.19% | 66.39% | |||
| Normalized Basic EPS | -161.05% | 68.23% | |||
| EPS Diluted | -154.19% | 66.39% | |||
| Normalized Diluted EPS | -161.05% | 68.23% | |||
| Average Basic Shares Outstanding | -0.03% | 0.04% | |||
| Average Diluted Shares Outstanding | -0.03% | 0.04% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||